{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:15:29Z","timestamp":1783376129206,"version":"3.54.6"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"28","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["CSASI21jun-0003"],"award-info":[{"award-number":["CSASI21jun-0003"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011105","name":"National University Cancer Institute, Singapore","doi-asserted-by":"publisher","award":["NR22NMR112OM"],"award-info":[{"award-number":["NR22NMR112OM"]}],"id":[{"id":"10.13039\/501100011105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.1038\/s41388-026-03830-9","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:19:38Z","timestamp":1781194778000},"page":"2840-2850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mes\/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-3026","authenticated-orcid":false,"given":"Vignesh","family":"Sundararajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ziyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal Ahmed","family":"Elfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-1593","authenticated-orcid":false,"given":"Tuan Zea","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuee Theng","family":"Kuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje Margret","family":"Wengner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh The","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maili","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Yee","family":"Chay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chit Fang","family":"Cheok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-5262","authenticated-orcid":false,"given":"David Shao Peng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"3830_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:3. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3830_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:11. https:\/\/doi.org\/10.1038\/nrc4019.","journal-title":"Nat Rev Cancer"},{"key":"3830_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jnci\/djy085","volume":"110","author":"MM Hoppe","year":"2018","unstructured":"Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110:7. https:\/\/doi.org\/10.1093\/jnci\/djy085.","journal-title":"J Natl Cancer Inst"},{"key":"3830_CR4","doi-asserted-by":"publisher","unstructured":"Ngoi NY, Sundararajan V, Tan DS. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int J Gynecol Cancer. 2020. https:\/\/doi.org\/10.1136\/ijgc-2020-001277.","DOI":"10.1136\/ijgc-2020-001277"},{"key":"3830_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622\u201336. https:\/\/doi.org\/10.1038\/nrm.2017.67.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3830_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.molcel.2017.05.001","volume":"66","author":"L Toledo","year":"2017","unstructured":"Toledo L, Neelsen KJ, Lukas J. Replication catastrophe: when a checkpoint fails because of exhaustion. Mol Cell. 2017;66:6. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.001.","journal-title":"Mol Cell"},{"key":"3830_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nature03485","volume":"434","author":"VG Gorgoulis","year":"2005","unstructured":"Gorgoulis VG, Vassiliou LVF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907\u201313. https:\/\/doi.org\/10.1038\/nature03485.","journal-title":"Nature"},{"key":"3830_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature05268","volume":"444","author":"J Bartkova","year":"2006","unstructured":"Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633\u20137. https:\/\/doi.org\/10.1038\/nature05268.","journal-title":"Nature"},{"key":"3830_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova J, Horejs\u00ed Z, Koed K, Kr\u00e4mer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864\u201370. https:\/\/doi.org\/10.1038\/nature03482.","journal-title":"Nature"},{"key":"3830_CR10","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352\u20135. https:\/\/doi.org\/10.1126\/science.1140735.","journal-title":"Science"},{"key":"3830_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pili\u00e9 PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278\u201393. https:\/\/doi.org\/10.1038\/s41571-024-00863-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"3830_CR12","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res. 2023;29:2800\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2444.","journal-title":"Clin Cancer Res"},{"key":"3830_CR13","doi-asserted-by":"publisher","unstructured":"Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017. https:\/\/doi.org\/10.1101\/gad.290957.116.","DOI":"10.1101\/gad.290957.116"},{"key":"3830_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:16. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0196.","journal-title":"Clin Cancer Res"},{"key":"3830_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/emmm.201201823","volume":"5","author":"TZ Tan","year":"2013","unstructured":"Tan TZ, Miow QH, Huang RYJ, Wong MK, Ye J, Lau JA, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer: a subtyping scheme for epithelial ovarian cancer. EMBO Mol Med. 2013;5:7. https:\/\/doi.org\/10.1002\/emmm.201201823.","journal-title":"EMBO Mol Med"},{"key":"3830_CR16","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network.","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:7353. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"key":"3830_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, Siemeister G, L\u00fccking U, Lefranc J, Wortmann L, Lienau P, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19:26\u201338. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0019.","journal-title":"Mol Cancer Ther"},{"key":"3830_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:7. https:\/\/doi.org\/10.1038\/nmeth.2089.","journal-title":"Nat Methods"},{"key":"3830_CR19","unstructured":"Davarinejad H. Quantifications of western blots with ImageJ. University of York; 2015."},{"key":"3830_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.xpro.2021.100978","volume":"2","author":"S Kilgas","year":"2021","unstructured":"Kilgas S, Kiltie AE, Ramadan K. Immunofluorescence microscopy-based detection of ssDNA foci by BrdU in mammalian cells. STAR Protoc. 2021;2:4. https:\/\/doi.org\/10.1016\/j.xpro.2021.100978.","journal-title":"STAR Protoc"},{"key":"3830_CR21","doi-asserted-by":"publisher","first-page":"12351","DOI":"10.1093\/nar\/gkae811","volume":"52","author":"GA Elfar","year":"2024","unstructured":"Elfar GA, Aning O, Ngai TW, Yeo P, Chan JWK, Sim SH, et al. p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis. Nucleic Acids Res. 2024;52:12351\u201377. https:\/\/doi.org\/10.1093\/nar\/gkae811.","journal-title":"Nucleic Acids Res"},{"key":"3830_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","volume":"2","author":"BM Gyori","year":"2014","unstructured":"Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement MV. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014;2:457\u201365. https:\/\/doi.org\/10.1016\/j.redox.2013.12.020.","journal-title":"Redox Biol"},{"key":"3830_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.celrep.2018.04.068","volume":"23","author":"DJ McGrail","year":"2018","unstructured":"McGrail DJ, Lin CCJ, Dai H, Mo W, Li Y, Stephan C, et al. Defective replication stress response is inherently linked to the cancer stem cell phenotype. Cell Rep. 2018;23:7. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.068.","journal-title":"Cell Rep"},{"key":"3830_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.5191","volume":"247","author":"TZ Tan","year":"2019","unstructured":"Tan TZ, Heong V, Ye J, Lim D, Low J, Choolani M, et al. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer. J Pathol. 2019;247:3. https:\/\/doi.org\/10.1002\/path.5191.","journal-title":"J Pathol"},{"key":"3830_CR25","doi-asserted-by":"publisher","DOI":"10.7603\/s40730-016-0022-8","volume":"3","author":"HTL Nguyen","year":"2016","unstructured":"Nguyen HTL, Nguyen ST, Van Pham P. Concise Review: 3D cell culture systems for anticancer drug screening. Biomed Res Ther. 2016;3:22. https:\/\/doi.org\/10.7603\/s40730-016-0022-8.","journal-title":"Biomed Res Ther"},{"key":"3830_CR26","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858\u201368. https:\/\/doi.org\/10.1074\/jbc.273.10.5858.","journal-title":"J Biol Chem"},{"key":"3830_CR27","doi-asserted-by":"publisher","first-page":"12855","DOI":"10.1074\/jbc.RA118.003740","volume":"293","author":"S Rodriguez-Acebes","year":"2018","unstructured":"Rodriguez-Acebes S, Mour\u00f3n S, M\u00e9ndez J. Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes. J Biol Chem. 2018;293:12855\u201361. https:\/\/doi.org\/10.1074\/jbc.RA118.003740.","journal-title":"J Biol Chem"},{"key":"3830_CR28","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1073\/pnas.1005031107","volume":"107","author":"E Petermann","year":"2010","unstructured":"Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA. 2010;107:16090\u20135. https:\/\/doi.org\/10.1073\/pnas.1005031107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3830_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1242\/jcs.096701","volume":"126","author":"M Yekezare","year":"2013","unstructured":"Yekezare M, G\u00f3mez-Gonz\u00e1lez B, Diffley JFX. Controlling DNA replication origins in response to DNA damage \u2013 inhibit globally, activate locally. J Cell Sci. 2013;126:1297\u2013306. https:\/\/doi.org\/10.1242\/jcs.096701.","journal-title":"J Cell Sci"},{"key":"3830_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.molcel.2020.12.010","volume":"81","author":"MM Genois","year":"2021","unstructured":"Genois MM, Gagn\u00e9 JP, Yasuhara T, Jackson J, Saxena S, Langelier MF, et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol Cell. 2021;81:784\u2013800.e8. https:\/\/doi.org\/10.1016\/j.molcel.2020.12.010.","journal-title":"Mol Cell"},{"key":"3830_CR31","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1158\/0008-5472.CAN-09-4691","volume":"70","author":"P Rimmel\u00e9","year":"2010","unstructured":"Rimmel\u00e9 P, Komatsu J, Hup\u00e9 P, Roulin C, Barillot E, Dutreix M, et al. Spi-1\/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res. 2010;70:6757\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4691.","journal-title":"Cancer Res"},{"key":"3830_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111397","volume":"40","author":"D Sarni","year":"2022","unstructured":"Sarni D, Barroso S, Shtrikman A, Irony-Tur Sinai M, Oren YS, Aguilera A, et al. Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability. Cell Rep. 2022;40:111397. https:\/\/doi.org\/10.1016\/j.celrep.2022.111397.","journal-title":"Cell Rep"},{"key":"3830_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","volume":"559","author":"A Maya-Mendoza","year":"2018","unstructured":"Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279\u201384. https:\/\/doi.org\/10.1038\/s41586-018-0261-5.","journal-title":"Nature"},{"key":"3830_CR34","doi-asserted-by":"publisher","unstructured":"Mansilla SF, Bertolin AP, Bergoglio V, Pillaire MJ, Gonz\u00e1lez Besteiro MA, Luzzani C, et al. Cyclin Kinase-independent role of p21CDKN1A in the promotion of nascent DNA elongation in unstressed cells. Botchan MR, editor. eLife. 2016;5:e18020. https:\/\/doi.org\/10.7554\/eLife.18020.","DOI":"10.7554\/eLife.18020"},{"key":"3830_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41586-021-03445-y","volume":"592","author":"D Simoneschi","year":"2021","unstructured":"Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, et al. CRL4AMBRA1 is a master regulator of D-type cyclins. Nature. 2021;592:789\u201393. https:\/\/doi.org\/10.1038\/s41586-021-03445-y.","journal-title":"Nature"},{"key":"3830_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-021-03422-5","volume":"592","author":"E Maiani","year":"2021","unstructured":"Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592:799\u2013803. https:\/\/doi.org\/10.1038\/s41586-021-03422-5.","journal-title":"Nature"},{"key":"3830_CR37","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41586-021-03474-7","volume":"592","author":"AC Chaikovsky","year":"2021","unstructured":"Chaikovsky AC, Li C, Jeng EE, Loebell S, Lee MC, Murray CW, et al. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D. Nature. 2021;592:794\u20138. https:\/\/doi.org\/10.1038\/s41586-021-03474-7.","journal-title":"Nature"},{"key":"3830_CR38","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gad.214080.113","volume":"27","author":"FB Couch","year":"2013","unstructured":"Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, B\u00e9tous R, et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013;27:1610. https:\/\/doi.org\/10.1101\/gad.214080.113.","journal-title":"Genes Dev"},{"key":"3830_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, et al. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163:246\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024.","journal-title":"Gynecol Oncol"},{"key":"3830_CR40","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","volume":"42","author":"F Simpkins","year":"2024","unstructured":"Simpkins F, Nasioudis D, Wethington SL, Martin LP, Tanyi JL, Latif NA, et al. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). J Clin Oncol. 2024;42:5510. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.5510.","journal-title":"J Clin Oncol"},{"key":"3830_CR41","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","volume":"31","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI). Int J Gynecol Cancer. 2021;31:1471\u20135. https:\/\/doi.org\/10.1136\/ijgc-2021-002973.","journal-title":"Int J Gynecol Cancer"},{"key":"3830_CR42","doi-asserted-by":"publisher","unstructured":"Xu H, George E, Gallo D, Medvedev S, Wang X, Datta A, et al. Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nat Commun. 2025:3112. https:\/\/doi.org\/10.1038\/s41467-025-58183-w.","DOI":"10.1038\/s41467-025-58183-w"},{"key":"3830_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:7. https:\/\/doi.org\/10.1016\/S1470-2045(20)30180-7.","journal-title":"Lancet Oncol"},{"key":"3830_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe6201","volume":"13","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Dai H, Lam TNA, Liang Y, Voorwerk L, et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021;13:eabe6201. https:\/\/doi.org\/10.1126\/scitranslmed.abe6201.","journal-title":"Sci Transl Med"},{"key":"3830_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04538-w","volume":"13","author":"V Azzoni","year":"2022","unstructured":"Azzoni V, Wicinski J, Macario M, Castagn\u00e9 M, Finetti P, Ambrosova K, et al. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death Dis. 2022;13:96. https:\/\/doi.org\/10.1038\/s41419-022-04538-w.","journal-title":"Cell Death Dis"},{"key":"3830_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.celrep.2022.111819","volume":"41","author":"H Schuhwerk","year":"2022","unstructured":"Schuhwerk H, Kleemann J, Gupta P, van Roey R, Armstark I, Kreileder M, et al. The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. Cell Rep. 2022;41:11. https:\/\/doi.org\/10.1016\/j.celrep.2022.111819.","journal-title":"Cell Rep"},{"key":"3830_CR47","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/path.6032","volume":"259","author":"V Sundararajan","year":"2023","unstructured":"Sundararajan V, Tan TZ, Lim D, Peng Y, Wengner AM, Ngoi NYL, et al. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition. J Pathol. 2023;259:2. https:\/\/doi.org\/10.1002\/path.6032.","journal-title":"J Pathol"},{"key":"3830_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/cancers14040997","volume":"14","author":"B Heitmeir","year":"2022","unstructured":"Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesm\u00fcller L. Circulating tumor cells in breast cancer patients: a balancing act between stemness, EMT features and DNA damage responses. Cancers. 2022;14:997. https:\/\/doi.org\/10.3390\/cancers14040997.","journal-title":"Cancers"},{"key":"3830_CR49","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3389\/fcell.2020.00647","volume":"8","author":"Y Hu","year":"2020","unstructured":"Hu Y, Taylor-Harding B, Raz Y, Haro M, Recouvreux MS, Taylan E, et al. Are epithelial ovarian cancers of the mesenchymal subtype actually intraperitoneal metastases to the ovary? Front Cell Dev Biol. 2020;8:647. https:\/\/doi.org\/10.3389\/fcell.2020.00647.","journal-title":"Front Cell Dev Biol"},{"key":"3830_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2018.11.019","volume":"152","author":"D Torres","year":"2019","unstructured":"Torres D, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Wang C, et al. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2019;152:223\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2018.11.019.","journal-title":"Gynecol Oncol"},{"key":"3830_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134:e175369. https:\/\/doi.org\/10.1172\/JCI175369.","journal-title":"J Clin Invest"},{"key":"3830_CR52","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djae098","volume":"116","author":"E Fontana","year":"2024","unstructured":"Fontana E, Rosen E, Lee EK, H\u00f8jgaard M, Mettu NB, Lheureux S, et al. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024;116:1439\u201349. https:\/\/doi.org\/10.1093\/jnci\/djae098.","journal-title":"J Natl Cancer Inst"},{"key":"3830_CR53","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, et al. First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res. 2024;30:2057\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2409.","journal-title":"Clin Cancer Res"},{"key":"3830_CR54","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1126\/scisignal.aaf8175","volume":"9","author":"J Antony","year":"2016","unstructured":"Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal. 2016;9:448. https:\/\/doi.org\/10.1126\/scisignal.aaf8175.","journal-title":"Sci Signal"},{"key":"3830_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/1878-0261.12425","volume":"13","author":"M Tan","year":"2019","unstructured":"Tan M, Asad M, Heong V, Wong MK, Tan TZ, Ye J, et al. The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Mol Oncol. 2019;13:4. https:\/\/doi.org\/10.1002\/1878-0261.12425.","journal-title":"Mol Oncol"},{"key":"3830_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s42003-023-05045-0","volume":"6","author":"XH Yeo","year":"2023","unstructured":"Yeo XH, Sundararajan V, Wu Z, Phua ZJC, Ho YY, Peh KLE, et al. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer. Commun Biol. 2023;6:660. https:\/\/doi.org\/10.1038\/s42003-023-05045-0.","journal-title":"Commun Biol"},{"key":"3830_CR57","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-16-2196","volume":"23","author":"S Kommoss","year":"2017","unstructured":"Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res. 2017;23:3794\u2013801. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2196.","journal-title":"Clin Cancer Res"},{"key":"3830_CR58","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/cancers13246215","volume":"13","author":"D King","year":"2021","unstructured":"King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, et al. Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells. Cancers. 2021;13:6215. https:\/\/doi.org\/10.3390\/cancers13246215.","journal-title":"Cancers"},{"key":"3830_CR59","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8:1404\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0474.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03830-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:05:06Z","timestamp":1783375506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":59,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026,7,28]]}},"alternative-id":["3830"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03830-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DSPT received research funding from AstraZeneca, Bayer, and Karyopharm and honoraria from AstraZeneca, MSD, Tessa Therapeutics, Novartis, Bayer, and Genmab. AMW was a permanent employee of BAYER AG at the time when the studies were performed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Statement for animal work: All in vivo xenograft studies adhered and performed in accordance to the SingHealth Animal Care and Use Committee (IACUC:2018\/SHS\/1356) guidelines on animal use and handling. The approval has been obtained from the committee and all methods were performed in accordance with the relevant guidelines and regulations. Statement for patient material: Usage of patient-derived materials has been approved by the National Health Group Domain Specific Review Board (DSRB), Reference: 2013\/00705. Written informed consent was obtained from each patient. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}